Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Chromosomal abnormalities in tumours were recognized at the end of the last century but their significance has only recently become clear. Distinct translocations in leukaemias and in solid tumours lead to the activation of proto-oncogene products or, more commonly, creation of tumour-specific fusion proteins. The proteins in both categories are often transcription factors and thus disruption of transcriptional control plays a major role in the aetiology of cancer. Fusion proteins formed after chromosomal translocations are common in a range of tumour types; these are unique tumour antigens and are therefore potential targets for therapy design.

Original publication

DOI

10.1038/372143a0

Type

Journal article

Journal

Nature

Publication Date

10/11/1994

Volume

372

Pages

143 - 149

Keywords

Gene Expression Regulation, Neoplastic, Humans, Leukemia-Lymphoma, Adult T-Cell, Neoplasms, Oncogene Proteins, Fusion, Proto-Oncogenes, Recombinant Fusion Proteins, Transcription Factors, Translocation, Genetic